SCHEMBL7167864

SCHEMBL7167864

C=CCC(C(N)=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.69
▸ TSHR P16473 2/20 0.58
▸ ALDH1A1 P00352 1/20 0.58
▸ CHRM3 P20309 4/20 0.46
▸ KCNH2 Q12809 2/20 0.46
▸ CHRM2 P08172 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MAPT P10636 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ CTDSP1 Q9GZU7 1/20 0.45
▸ MEN1 O00255 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ KCNN4 O15554 5/20 0.41
▸ DRD2 P14416 1/20 0.40
▸ OPRM1 P35372 1/20 0.40
▸ DRD3 P35462 1/20 0.40
▸ SLC22A2 O15244 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8358191 0.85 ALDH1A1 (0.67) HTTTSHRALDH1A1CHRM3KCNH2
SCHEMBL8661754 0.82 OPRM1 (0.57) HTTTSHRALDH1A1CHRM3KCNH2
SCHEMBL8071145 0.79 CHRM3 (0.50) HTTTSHRALDH1A1CHRM3KCNH2
SCHEMBL15848242 0.77 ALDH1A1 (0.53) HTTTSHRALDH1A1CHRM3CHRM2
SCHEMBL11021099 0.76 MAPT (0.52) HTTTSHRCHRM3KCNH2CHRM2
SCHEMBL3465944 0.76 HTT (0.81) HTTTSHRALDH1A1CHRM3KCNH2
SCHEMBL3465945 0.76 HTT (0.81) HTTTSHRALDH1A1CHRM3KCNH2
SCHEMBL1908316 0.76 ALDH1A1 (0.65) HTTTSHRALDH1A1CYP2D6KMT2A
SCHEMBL3613086 0.76 ALDH1A1 (0.65) HTTTSHRALDH1A1CYP2D6KMT2A
SCHEMBL10685798 0.75 CHRM3 (0.50) HTTTSHRCHRM3KCNH2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6573282-B1 Compositions for treatment of peripheral hyperalgesia are provided. The compositions contain an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors ADOLOR CORPORATION 2003-06-03 — — US disclosed
US-5994372-A ANTIDIARRHEA COMPOUND REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-11-30 — — US disclosed
EP-0852494-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-15 — — EP disclosed
WO-1997009973-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-03-20 — — WO disclosed
Send feedback